Innate Pharma S.A (NASDAQ: IPHA) has been gaining traction since it went public in September. The company has also made a number of positive announcements since that time. A few days ago, on the 2nd of December, the company announced that it had been certified as a great place to work by an independent rating institute. The rating was based on a number of factors that were based on anonymous surveys on the company’s employees. 

According to the company CEO, Mondher Mahjoubi, this award reflects on the company’s positive culture. He also stated that, they were proud of the award, arguing that it was a reflection of its collaborative culture, one where the management always engages with employees.

The great place to work award has been in place since 1992.  It is an authority in matters of organizational culture, and since its inception, it has surveyed more than 100 million employees from all across the world. Their data has been used by some of the biggest corporations across the world across over 60 countries. Their credibility reflects positively on IPHA.

Earlier, on the 12th of November, the company released its Q3 results that included news on its partnerships. The company announced that it had partnered with AstraZeneca to develop phase 3 of its randomized clinical trial for Monalizumab. The evaluation will be on patients suffering from recurrent metastatic squamous cell carcinoma and had been earlier exposed to immune checkpoint inhibitors. The company announced that, it expects to initiate the trial in 2020, once it gets regulatory approval.

From the charts, the stock has been gaining since IPO with periodic corrections.

About Innate Pharma S.A

Innate Pharma S.A is a biopharma company that creates therapeutic antibodies for treating cancer. Some of its treatments include IPH4102 and IPH5201. The company has licensing agreements with multiple biopharma companies including Sanofi and Bristol-Myers Squibb. t has its headquarters in Marseille, France.